Tags

Type your tag names separated by a space and hit enter

Stem Cell-Based Therapy for Diseases of the Retinal Pigment Epithelium: From Bench to Bedside.
Semin Ophthalmol. 2016; 31(1-2):25-9.SO

Abstract

Age-related macular degeneration (AMD) represents a leading cause of blindness in the elderly, and Stargardt's macular dystrophy (SMD) is the most common form of juvenile-onset macular degeneration. Dry AMD and SMD share an underlying pathophysiology, namely dysfunction and ultimately loss of the retinal pigment epithelium (RPE), suggesting that RPE transplantation may offer a potential treatment strategy for both patient populations. Stem cells have emerged as a promising source of replacement RPE. During the past 15 years, extraordinary strides have been made in the identification, characterization, and differentiation of stem cells. Recently, this large body of basic science and preclinical research has been translated to patient care with the publication of results from Phase 1/2 trials demonstrating safety of transplantation of human embryonic stem cell (hESC)-derived RPE into patients with AMD and SMD. While significant challenges remain before dry AMD and SMD become treatable diseases, the goal has become more tangible.

Authors+Show Affiliations

a Harvard Medical School, Massachusetts Eye and Ear Infirmary , Boston , Massachusetts , USA.a Harvard Medical School, Massachusetts Eye and Ear Infirmary , Boston , Massachusetts , USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

26959126

Citation

Sachdeva, Mira M., and Dean Eliott. "Stem Cell-Based Therapy for Diseases of the Retinal Pigment Epithelium: From Bench to Bedside." Seminars in Ophthalmology, vol. 31, no. 1-2, 2016, pp. 25-9.
Sachdeva MM, Eliott D. Stem Cell-Based Therapy for Diseases of the Retinal Pigment Epithelium: From Bench to Bedside. Semin Ophthalmol. 2016;31(1-2):25-9.
Sachdeva, M. M., & Eliott, D. (2016). Stem Cell-Based Therapy for Diseases of the Retinal Pigment Epithelium: From Bench to Bedside. Seminars in Ophthalmology, 31(1-2), 25-9. https://doi.org/10.3109/08820538.2015.1115253
Sachdeva MM, Eliott D. Stem Cell-Based Therapy for Diseases of the Retinal Pigment Epithelium: From Bench to Bedside. Semin Ophthalmol. 2016;31(1-2):25-9. PubMed PMID: 26959126.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Stem Cell-Based Therapy for Diseases of the Retinal Pigment Epithelium: From Bench to Bedside. AU - Sachdeva,Mira M, AU - Eliott,Dean, PY - 2016/3/10/entrez PY - 2016/3/10/pubmed PY - 2016/10/26/medline KW - Age-related macular degeneration KW - retinal pigment epithelium KW - stargardt’s macular dystrophy KW - stem cells KW - transplantation SP - 25 EP - 9 JF - Seminars in ophthalmology JO - Semin Ophthalmol VL - 31 IS - 1-2 N2 - Age-related macular degeneration (AMD) represents a leading cause of blindness in the elderly, and Stargardt's macular dystrophy (SMD) is the most common form of juvenile-onset macular degeneration. Dry AMD and SMD share an underlying pathophysiology, namely dysfunction and ultimately loss of the retinal pigment epithelium (RPE), suggesting that RPE transplantation may offer a potential treatment strategy for both patient populations. Stem cells have emerged as a promising source of replacement RPE. During the past 15 years, extraordinary strides have been made in the identification, characterization, and differentiation of stem cells. Recently, this large body of basic science and preclinical research has been translated to patient care with the publication of results from Phase 1/2 trials demonstrating safety of transplantation of human embryonic stem cell (hESC)-derived RPE into patients with AMD and SMD. While significant challenges remain before dry AMD and SMD become treatable diseases, the goal has become more tangible. SN - 1744-5205 UR - https://www.unboundmedicine.com/medline/citation/26959126/Stem_Cell_Based_Therapy_for_Diseases_of_the_Retinal_Pigment_Epithelium:_From_Bench_to_Bedside_ L2 - https://www.tandfonline.com/doi/full/10.3109/08820538.2015.1115253 DB - PRIME DP - Unbound Medicine ER -